Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
A woman in her 60s died three days after receiving Pfizer/BioNTech’s COVID-19 vaccine in Japan under the country’s initial inoculation campaign targeting healthcare professionals, the Ministry of Health, Labor and Welfare (MHLW) said on March 2. The cause of the…
To read the full story
Related Article
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Second Case of TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
December 27, 2021
- Japan Panels Agree to Add Myocarditis as ADRs for Pfizer, Moderna Vaccines
December 6, 2021
- TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
November 15, 2021
- MHLW Panels Continue to See No Major Safety Concerns for COVID-19 Jabs
October 25, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW Panels
October 4, 2021
- Causal Link between Deaths and Recalled Batch of Moderna Jab “Indeterminable”
September 13, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
August 6, 2021
- Panels Agree to Add Risk of Thrombocytopenia to AstraZeneca Vaccine Label
July 27, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
July 9, 2021
- No Major Concerns over Safety of Moderna, Pfizer COVID-19 Vaccines: MHLW
June 11, 2021
- MHLW Panels to Analyze Group-Based Data for Post-COVID-19 Vaccination Deaths
May 27, 2021
- No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
May 14, 2021
- Don’t Take Vaccines If You Feel Ill: Safety Panels to Elderly
April 26, 2021
- COVID-19 Vaccine Reactions More Common in Women, Younger People: MHLW Study
April 12, 2021
- Vaccine Safety Panels to Evaluate Suspected Anaphylaxis Cases Based on Pfizer’s Reports
April 12, 2021
- 35.6% of Pfizer Vaccine Recipients Developed Fevers after 2nd Shot, Higher Incidence in Women: MHLW
March 29, 2021
- No Significant Concerns Observed with Pfizer COVID-19 Vaccine: Japan Safety Panels
March 15, 2021
- Japan Confirms 1st Case of Anaphylaxis from COVID-19 Vaccination
March 8, 2021
REGULATORY
- PMDA to Adopt General-Purpose AI in FY2025, Eyes Specialized Tools for Reviews and Safety Work
December 8, 2025
- Japan Likely to Extend Generic-Name Prescribing Premium to Biologics to Spur Biosimilars
December 8, 2025
- Aspirin, CAR-T and Other Products under PMDA Safety Review
December 8, 2025
- R&D Tax Credit Draws Broad Calls for Maintenance, Expansion: LDP Meeting
December 8, 2025
- Another LDP Study Group Submits Emergency Proposal Urging Drug Pricing Overhaul
December 5, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…